Can a pill keep blood cancer away after transplant?
NCT ID NCT04980404
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial tests whether the oral drug Inqovi (decitabine/cedazuridine) can help prevent myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) from returning after a stem cell transplant. About 22 adults who have had a reduced-intensity transplant will take Inqovi as maintenance therapy. The main goal is to find the safest and most tolerable dose schedule.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Inqovi (decitabine and cedazuridine combination tablet)
- What this could lead to
- If it works, this could point toward a way to keep MDS or CMML from coming back after a stem cell transplant.
- What could go wrong
- This is a very early phase 1 trial with only 22 people, so it is mainly checking safety and dosing. It may not show a clear benefit, and side effects like graft-versus-host disease are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can a Two-Drug combo tame a rare blood cancer?